Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a...
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief...
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to...
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 1.48514851485 | 2.02 | 2.27 | 1.86 | 16044 | 2.14755068 | CS |
| 4 | -0.61 | -22.9323308271 | 2.66 | 2.9443 | 1.58 | 26127 | 2.12832112 | CS |
| 12 | -2.1 | -50.6024096386 | 4.15 | 4.2 | 1.58 | 34321 | 2.90605151 | CS |
| 26 | -1.95 | -48.75 | 4 | 4.9 | 1.58 | 125153 | 3.66762201 | CS |
| 52 | -1.95 | -48.75 | 4 | 4.9 | 1.58 | 125153 | 3.66762201 | CS |
| 156 | -1.95 | -48.75 | 4 | 4.9 | 1.58 | 125153 | 3.66762201 | CS |
| 260 | -1.95 | -48.75 | 4 | 4.9 | 1.58 | 125153 | 3.66762201 | CS |
| Símbolo | Precio | Vol. |
|---|---|---|
| MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 1.0851 (2.37%) | 248.68M |
| SOARVolato Group Inc | US$ 0.3738 (68.53%) | 178.71M |
| OPTTOcean Power Technologies Inc | US$ 0.3938 (-43.74%) | 90.28M |
| KORUDirexion Daily South Korea Bull 3X Shares | US$ 4.30 (-6.93%) | 48.71M |
| EEMiShares MSCI Emerging Markets | US$ 43.52 (0.21%) | 41.09M |
JPetroInc
2 meses hace
JPetroInc
2 meses hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
